11–13 October 2023 Milan
![]() |
![]() |
![]() |
![]() |
1-P | Inclusion of optic neuritis improves the performance of McDonald 2017 criteria in Hispanic people with suspected multiple sclerosis | Lilyana Amezcua | ![]() |
![]() |
|||
2-P | How Well Do Junior Neurology Residents Recognize Multiple Sclerosis? Analysis of the Close the Loop Resident Clinical Acumen Project | Claudia Zbrzeski | ![]() |
![]() |
|||
3-P | Clinical and radiological phenotype of adult-onset neurogenetic diseases mimicking multiple sclerosis: a multinational observational study | Gabrielle Macaron | ![]() |
![]() |
|||
18-P | Humoral signatures of MOG-antibody associated disease | Jan Lünemann | ![]() |
![]() |
|||
21-P | Clinical predictors of outcomes in pediatric myelin oligodendrocyte glycoprotein antibody disease | Alexandra Kornbluh | ![]() |
![]() |
|||
42-P | Patterns and Predictors of Conversion from Relapsing-Remitting to Secondary Progressive MS: A Longitudinal Study Using the Danish Multiple Sclerosis Registry | Melinda Magyari | ![]() |
![]() |
|||
45-P | Disease modifying therapy use among people living with multiple sclerosis based on socioeconomic status and urban/rural residence: a retrospective cohort study from Alberta, Canada | Erin Balcom | ![]() |
![]() |
|||
47-P | Epidemiology of Relapsing Remitting Multiple Sclerosis in Chile between 2010 and 2021 | Lorna Galleguillos | ![]() |
![]() |
|||
54-P | Prognostic factors of Disease Activity in Newly-diagnosed Teriflunomide Treated Patients with Multiple Sclerosis - A Nationwide Danish Study | Mie Reith Mahler | ![]() |
![]() |
|||
62-P | Evidence of disease activity during pregnancy and post-partum in MS patients treated with high-efficacy therapies: a monocentric retrospective study | Oussama Sahloul | ![]() |
![]() |
|||
71-P | Performance of gold-standard cognitive measures for detecting change over time: Longitudinal analysis of retrospective data | Victoria Leavitt | ![]() |
![]() |
|||
87-P | Patient-reported factors impacting well-being in individuals with multiple sclerosis - a cross-sectional study | Sabrina Islamoska | ![]() |
![]() |
|||
94-P | Elevated Incidence and Prevalence of Peripartum Mental Illness in Women with Multiple Sclerosis | Ruth Ann Marrie | ![]() |
![]() |
|||
140-P | Age-associated change in Th17 and cytokine response in Multiple Sclerosis | Zongqi Xia | ![]() |
![]() |
|||
150-P | Cytomegalovirus in multiple sclerosis patients: how does it interact with the infection by Epstein-Barr virus and human herpesvirus 6A/B? | Roberto Alvarez-Lafuente | ![]() |
![]() |
|||
151-P | Environmental risk factors in multiple sclerosis. FRAMES study. | Roberto Álvarez-Lafuente | ![]() |
![]() |
|||
162-P | Ublituximab Reduces Thalamic Volume Loss and New Lesion Formation in Participants of the ULTIMATE I & II Phase 3 Studies | Victoria Findlen | ![]() |
![]() |
|||
192-P | Contribution of 7T brain MRI to the detection of cortical lesions at the earliest stage of multiple sclerosis. | Jean Pelletier | ![]() |
![]() |
|||
203-P | Depicting longitudinal MS disease course using lesion parenchymal fraction (LPF): a quantified expression of the topographical model of MS | Stephen Krieger | ![]() |
![]() |
|||
219-P | Creation and performance of the International MOGAD Diagnostic Criteria | Brenda Banwell | ![]() |
![]() |
|||
237-P | Immune cell subpopulations and serum neurofilament light chain are associated with increased risk of disease worsening in multiple sclerosis | Synne Brune-Ingebretsen | ![]() |
![]() |
|||
239-P | Serum neurofilaments are a reliable biomarker to early detect PML in Multiple Sclerosis patients | Antonio Bertolotto | ![]() |
![]() |
|||
276-P | Phase III MIRANTIBUS trial: results of 48 weeks treatment with divozilimab versus teriflunomide in relapsing multiple sclerosis. | Alexey Boyko | ![]() |
![]() |
|||
282-P | Phase I trial of faecal microbiota transplantation in MS | Bob van Oosten | ![]() |
![]() |
|||
295-P | VISIONARY-MS Topline Results: A Phase 2, Randomized, Double-Blind, Parallel Group, Placebo-controlled Study to Assess the Safety and Efficacy of CNM-Au8, a Catalytically Active Gold Nanocrystal Suspension in Relapsing Multiple Sclerosis | Heidi Beadnall | ![]() |
![]() |
|||
296-P | harnessing the endogenous adaptive response to hypoxia-ischemia as a therapy for neurodegeneration in multiple sclerosis | Carlos Camara | ![]() |
![]() |
|||
309-P | DISCOntinuation of disease-modifying therapies in Multiple Sclerosis (DISCOMS): Primary results of the extension trial | John Corboy | ![]() |
![]() |
|||
314-P | Endogenous IgG4 Concentration Impacts Natalizumab Arm Exchange and Intact Drug Pharmacokinetics | Bradley Messmer | ![]() |
![]() |
|||
323-P | The role of ganglion cell inner plexiform layer thickness in evaluating the neuroprotective role of phenytoin in the visual pathway | Srikirti Kodali | ![]() |
![]() |
|||
325-P | Risk of cardiovascular disease in patients treated with fingolimod compared to natalizumab: A nationwide cohort study in Denmark | Elisabeth Framke | ![]() |
![]() |
|||
331-P | Stopping Fingolimod is associated with a high risk of radiological disease reactivation | Rolf Holm | ![]() |
![]() |
|||
345-P | Disparities in DMT Treatment Access: Demographic and neurocognitive differences between MS patients currently treated versus not treated with disease-modifying therapies | Victoria Leavitt | ![]() |
![]() |
|||
359-P | Efficacy and safety of diroximel fumarate compared with interferon beta-1a in relapsing-remitting multiple sclerosis: Propensity Score Matching Analysis of Phase 3 Data from EVOLVE-MS-1 and DECIDE | Christin Henning | ![]() |
![]() |
|||
360-P | Incidence of new menstrual cycle disorders in a cohort of 120 women with multiple sclerosis treated with cladribine: a single-arm oberservational multi-center cohort study | Birte Elias-Hamp | ![]() |
![]() |
|||
383-P | Is Fatigue in MS the same one manifesting as Wearing-off Symptom in Natalizumab treated patients? | Giuseppe Magro | ![]() |
![]() |
|||
395-P | Trait Conscientiousness and Multiple Sclerosis: Predicting Disease Progression and Assessing the Effects of an App-Supported Behavioral Intervention | Michael Jaworski | ![]() |
![]() |
|||
417-P | Comparison of Vision-Related Quality of Life in AQP4 NMOSD and MOGAD | Adnan A. Gassan | ![]() |
![]() |
|||
418-P | Myelin Oligodendrocyte Glycoprotein (MOG) Antibody Disease and MOG/AQP4 Testing Landscape in Canada | Jodie Burton | ![]() |
![]() |
|||
423-P | Assessing the performance of cell based assays for MOGAD in the real world setting of a resource poor region - Impact of the international MOGAD diagnostic criteria | Lekha Pandit | ![]() |
![]() |
|||
424-P | Depression and Cognition in Multiple Sclerosis: Longitudinal Evidence of a Specific Link to Executive Control | Jordyn Anderson | ![]() |
![]() |
|||
450-P | The multiple sclerosis prodrome: Rates of physician visits were elevated in the 15 years before a first demyelinating event and differed by age and sex; an international matched cohort study. | Helen Tremlett | ![]() |
![]() |
|||
451-P | Chronic infections and malignancy screening in Mexican patients with multiple sclerosis before initiating disease modifying treatments. | lizeth zertuche | ![]() |
![]() |
|||
453-P | Clinical outcomes and treatment strategy of multiple sclerosis in China: Results from a real-world cross-sectional survey | Wenhao Wang | ![]() |
![]() |
|||
463-P | Pregnancy reduces the risk of reaching irreversible EDSS 3 in women with multiple sclerosis, but theres a catch! | Vilija Jokubaitis | ![]() |
![]() |
|||
464-P | RESPONSE, a French cohort of pregnant women with MS and related disorders and their children until the age of 6. Protocol and baseline characteristics. | Sandra Vukusic | ![]() |
![]() |
|||
485-P | MS Falls InsightTrack (MS-FIT): Design and Stakeholder Perspectives on a Closed-loop Falls Monitoring and Prevention Application for MS Clinical Practice | Valerie Block | ![]() |
![]() |
|||
490-P | The socio-economic burden of AQP4-antibody seropositive NMOSD: a nationwide registry-based study | Viktoria Papp | ![]() |
![]() |
|||
494-P | Comorbidity in the aging population with multiple sclerosis -- A nationwide cross-sectional study | Rolf Holm | ![]() |
![]() |
|||
510-P | Pathogenic cerebrospinal fluid antibodies in oligoclonal band-negative primary progressive MS patients | Jamie Wong | ![]() |
![]() |
|||
519-P | A single cell multi-omics map of cell type specific mechanistic drivers of multiple sclerosis lesions | Maria Louise Elkjr | ![]() |
![]() |
|||
527-P | SARS-CoV-2 mRNA vaccination affects antibody and cellular immune responses after B-cell depletion therapies | Erin Longbrake | ![]() |
![]() |
|||
530-P | Cervical lymph nodes in patients with multiple sclerosis show an overrepresentation of memory B cells and a disturbed germinal center reaction | Sini Laakso | ![]() |
![]() |
|||
538-P | Expanded T lymphocyte clones in the cerebrospinal fluid of multiple sclerosis patients are specific for autologous Epstein-Barr virus infected B lymphocytes. | John Lindsey | ![]() |
![]() |
|||
548-P | In vitro infection of CNS-derived cells with Epstein-Barr virus using a B-cell transfer method | Roberto Alfonso | ![]() |
![]() |
|||
551-P | Inverse association between mediterranean diet and risk of multiple sclerosis | Lars Alfredsson | ![]() |
![]() |
|||
574-P | Choroid plexus volume and slowly expanding lesions as inflammatory markers in relapsing multiple sclerosis. | Muhammad Raghib | ![]() |
![]() |
|||
575-P | Choroid plexus volume correlates with advanced MRI metrics in relapsing multiple sclerosis. | Muhammad Raghib | ![]() |
![]() |
|||
599-P | The value of magnetic resonance imaging of the optic nerve for the diagnosis of multiple sclerosis in patients with acute optic neuritis. | Gorm Pihl-Jensen | ![]() |
![]() |
|||
615-P | Neurodegeneration may occur without evidence of clinical or neuroinflammatory relapse in recently-diagnosed relapsing-remitting multiple sclerosis | Rozanna Meijboom | ![]() |
![]() |
|||
634-P | Plasma IgG Aggregates as Biomarkers for MS and for Diagnosing SPMS | Xiaoli Yu | ![]() |
![]() |
|||
638-P | Trends, Features, and Utility of Testing Myelin Oligodendrocyte Glycoprotein Autoantibodies in CSF | Jodie Burton | ![]() |
![]() |
|||
663-P | Stool glial fibrillary acidic protein is a biomarker of progressive multiple sclerosis and predicts disease worsening | Luke Schwerdtfeger | ![]() |
![]() |
|||
672-P | Improving Precision Medicine for Multiple Sclerosis with Uncertainty-Aware Causal Models | Jean-Pierre Falet | ![]() |
![]() |
|||
700-P | Inhibiting CEMIP Activity in Demyelinating Lesions Promotes Functional Remyelination | Larry Sherman | ![]() |
![]() |
|||
703-P | The neuroprotective potential of mesenchymal stem cells from bone marrow and human exfoliated deciduous teeth in murine models of multiple sclerosis | Torbjrn Krkenes | ![]() |
![]() |
|||
708-P | Reduction in Absolute Lymphocyte Count in Patients Transitioning from Dimethyl Fumarate to Diroximel Fumarate. | Kyle Smoot | ![]() |
![]() |
|||
717-P | Prediction of gammaglobulin decrease during rituximab treatment in MS | Sandra Kallin | ![]() |
![]() |
|||
735-P | New methods to estimate the effect of disease modifying treatment on disability in multiple sclerosis in open observational cohort studies. | Melinda Magyari | ![]() |
![]() |
|||
736-P | Descriptive demographic and clinical characteristics for Alemtuzumab treated patients with MS vs. other disease modifying therapies treated patients with MS: Preliminary results of a feasibility analysis | Jian-Yu E | ![]() |
![]() |
|||
742-P | A Retrospective Analysis of Natalizumab First-line Versus Later-line Use in Multiple Sclerosis Treatment: Evidence from a US Claims Database Study | Mattia Gianinazzi | ![]() |
![]() |
|||
760-P | Grey Matter Structural Changes and their Correlation with Tremor Severity in Multiple Sclerosis: A Case-Control Study | Ahmed Bayoumi | ![]() |
![]() |
|||
761-P | When does multiple sclerosis (MS) start? Findings from an international pediatric-onset MS population suggests higher than expected health care use from birth | Helen Tremlett | ![]() |
![]() |
|||
766-P | Increased Aerobic Glycolysis in Normal Appearing White Matter of Multiple Sclerosis Patients | Matthew Brier | ![]() |
![]() |
|||
768-P | Analysis of the Global Landscape of Multiple Sclerosis Research | Bruce Bebo | ![]() |
![]() |
|||
780-P | The Role of Surveillance MRI in Paediatric-onset MOGAD and NMOSD: A Retrospective Cohort Study | Paridhi Shah | ![]() |
![]() |
11–13 October 2023 Milan
![]() |
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. ![]() To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. ![]() |
![]() |
||
![]() |
|